نبذة مختصرة : The aim of the study was to evaluate the possibility of using lopinavir/ritonavir (LPV/RTV) alone as maintenance therapy in HIV-infected individuals with virological suppression. This was a single-armed single-centre pilot trial. Asymptomatic HIV-infected patients on highly active antiretroviral therapy (HAART) including LPV/RTV and with plasma HIV RNA less than 40 copies/mL for at least 6 months were enrolled in the study during which they continued with LPV/RTV alone. The intention was to recruit 25 patients to be followed for 2 years. Viral failure was defined as two consecutive HIV RNA measurements greater than 40 copies/mL. Nadir and baseline CD4 cell counts highest ever HIV RNA load time with undetectable viraemia before monotherapy number of previous antiretroviral (ARV) regimens and gene polymorphism at CYP3A4 and CYP3A5 were evaluated. All patients (27) completed the study. Their median age was 43 years and 66% were men. Ten patients (37%) failed to maintain virological suppression (the median time to HIV rebound was 10.5 months with a range of 4-23 months). One patient developed full resistance to LPV and another developed neurocognitive impairment while on LPV/RTV which improved after HAART reintroduction. There were no differences between failures and nonfailures according to the analysed parameters. Patients with viral failure were successfully resuppressed. LPV/RTV maintenance therapy was associated with 37% failure a higher than expected failure rate. In order to ensure that unnecessary risks are not being taken in patients on LPV/RTV this finding should be further evaluated in large randomized trials for longer periods of follow-up. (authors)
Processing Request
No Comments.